PolyNovo Completes Patient Recruitment for NovoSorb BTM Clinical Trial; Shares Down 4%

MT Newswires Live09-04

PolyNovo (ASX:PNV) completed the recruitment for its pivotal clinical trial assessing the effectiveness of its treatment for traumatic wounds, with 120 patients enrolled, according to a Wednesday filing with the Australian bourse.

The randomized controlled trial aims to compare PolyNovo's NovoSorb BTM to the standard of care for third-degree, full-thickness burns.

The Australian medical technology company is now in talks with the US Food and Drug Administration on the timing of the premarket approval filing for an on-label indication supporting the use of NovoSorb BTM in full-thickness burns, the filing stated.

PolyNovo's shares were down over 4% in recent Wednesday trade.

Price (AUD): $2.31, Change: $-0.11, Percent Change: -4.36%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464319302?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-04 12:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2464319302","market":"sg","top_or_hot":-1,"title":"PolyNovo Completes Patient Recruitment for NovoSorb BTM Clinical Trial; Shares Down 4%","media":"MT Newswires Live","content":"<html><body><p> PolyNovo (ASX:PNV) completed the recruitment for its pivotal clinical trial assessing the effectiveness of its treatment for traumatic wounds, with 120 patients enrolled, according to a Wednesday filing with the Australian bourse.</p><p>The randomized controlled trial aims to compare PolyNovo's NovoSorb BTM to the standard of care for third-degree, full-thickness burns.</p><p>The Australian medical technology company is now in talks with the US Food and Drug Administration on the timing of the premarket approval filing for an on-label indication supporting the use of NovoSorb BTM in full-thickness burns, the filing stated.</p><p>PolyNovo's shares were down over 4% in recent Wednesday trade.</p><p>Price (AUD): $2.31, Change: $-0.11, Percent Change: -4.36%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolyNovo Completes Patient Recruitment for NovoSorb BTM Clinical Trial; Shares Down 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyNovo Completes Patient Recruitment for NovoSorb BTM Clinical Trial; Shares Down 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-04 12:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PolyNovo (ASX:PNV) completed the recruitment for its pivotal clinical trial assessing the effectiveness of its treatment for traumatic wounds, with 120 patients enrolled, according to a Wednesday ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XAO.AU","symbol_name":"标普/澳交所 普通股指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2464319302","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464319302","pubTimestamp":1725425322,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PolyNovo  completed the recruitment for its pivotal clinical trial assessing the effectiveness of its treatment for traumatic wounds, with 120 patients enrolled, according to a Wednesday filing with the Australian bourse.The randomized controlled trial aims to compare PolyNovo's NovoSorb BTM to the standard of care for third-degree, full-thickness burns.The Australian medical technology company is now in talks with the US Food and Drug Administration on the timing of the premarket approval filing for an on-label indication supporting the use of NovoSorb BTM in full-thickness burns, the filing stated.PolyNovo's shares were down over 4% in recent Wednesday trade.Price : $2.31, Change: $-0.11, Percent Change: -4.36%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XAO.AU":"标普/澳交所 普通股指数","BK4137":"综合支持服务","AUD":"Audacy Inc.","PNV.AU":"POLYNOVO LTD","XJO.AU":"标普/澳交所 200指数","BK7508":"医药生物股","BTM":"Bitcoin Depot Inc.","BK7126":"医疗保健用品","XKO.AU":"标普/澳交所 300指数","BK4125":"广播"},"translate_title":"PolyNovo完成NovoSorb BTM临床试验的患者招募；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"BTM":1,"PNV.AU":0.9,"XAO.AU":0.81,"XJO.AU":0.81,"XKO.AU":0.81},"content_text":"PolyNovo (ASX:PNV) completed the recruitment for its pivotal clinical trial assessing the effectiveness of its treatment for traumatic wounds, with 120 patients enrolled, according to a Wednesday filing with the Australian bourse.The randomized controlled trial aims to compare PolyNovo's NovoSorb BTM to the standard of care for third-degree, full-thickness burns.The Australian medical technology company is now in talks with the US Food and Drug Administration on the timing of the premarket approval filing for an on-label indication supporting the use of NovoSorb BTM in full-thickness burns, the filing stated.PolyNovo's shares were down over 4% in recent Wednesday trade.Price (AUD): $2.31, Change: $-0.11, Percent Change: -4.36%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464319302"}